These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 21607556)
21. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Fornaro L; Masi G; Bursi S; Loupakis F; Vasile E; Antonuzzo A; Chiara S; Pfanner E; Di Paolo A; Bocci G; Del Tacca M; Falcone A Cancer Chemother Pharmacol; 2009 Apr; 63(5):965-9. PubMed ID: 18839174 [TBL] [Abstract][Full Text] [Related]
22. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776 [TBL] [Abstract][Full Text] [Related]
23. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583 [TBL] [Abstract][Full Text] [Related]
24. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415 [TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855 [TBL] [Abstract][Full Text] [Related]
26. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related]
27. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282 [TBL] [Abstract][Full Text] [Related]
28. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194 [TBL] [Abstract][Full Text] [Related]
29. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577 [TBL] [Abstract][Full Text] [Related]
30. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. Zhao WY; Chen DY; Qi Q Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259 [TBL] [Abstract][Full Text] [Related]
32. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730 [TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706 [TBL] [Abstract][Full Text] [Related]
34. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Koopman M; Antonini NF; Douma J; Wals J; Honkoop AH; Erdkamp FL; de Jong RS; Rodenburg CJ; Vreugdenhil G; Akkermans-Vogelaar JM; Punt CJ Ann Oncol; 2006 Oct; 17(10):1523-8. PubMed ID: 16873425 [TBL] [Abstract][Full Text] [Related]
35. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490 [TBL] [Abstract][Full Text] [Related]
36. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214 [TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478 [TBL] [Abstract][Full Text] [Related]
39. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
40. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]